Drug
Kyv101
Kyv101: highest development phase Phase 1/2, developed by Kyverna Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Kyverna Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| KYV101 NCT06475495 | Phase 1/2 | Rheumatoid Arthritis |
Latest
No recent events.
Follow Kyv101 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.